Insmed Incorporated (Nasdaq: INSM) today reported financial results for the fourth quarter and year ended December 31, 2014.
Highlights of the fourth quarter of 2014 and recent weeks include:
•Received validation of the Company’s Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ARIKAYCE following the approval of the Pediatric Investigation Plan (PIP) by the EMA’s Pediatric Committee;
Help employers find you! Check out all the jobs and post your resume.
Highlights of the fourth quarter of 2014 and recent weeks include:
•Received validation of the Company’s Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ARIKAYCE following the approval of the Pediatric Investigation Plan (PIP) by the EMA’s Pediatric Committee;
Help employers find you! Check out all the jobs and post your resume.
